Pharmaceuticals Japan

Japan Plasma-Derived Therapies Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Japan Plasma-Derived Therapies Market Industry Trends and Forecast to 2034: Segmented by (Product, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Japan · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $2.33 Bn Placeholder estimate
Estimate 2025 $2.50 Bn 6.8% of the global market
Projected 2034 $4.84 Bn 93.3% Adds $2.34 Bn over 9 forecast years
CAGR 2025–2034 7.6% Faster than 39% of 180 Pharmaceuticals markets here
Key players 5
  • Japan is 6.83% of the global market.
  • In APAC, the largest is China at $2.87 Bn.
  • Fastest growing: India at 10% a year.
  • Japan ranks 2nd of 10 by size in APAC.

Market size projection

Japan

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$2.34 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Plasma-Derived Therapies Market market size by year, Japan
YearMarket sizeChange that yearSince 2025
2024 (estimate) $2.33 Bn — —
2025 (base) $2.50 Bn +$176.8 Mn —
2026 (forecast) $2.69 Bn +$190.3 Mn +7.6%
2027 (forecast) $2.90 Bn +$204.7 Mn +15.8%
2028 (forecast) $3.12 Bn +$220.3 Mn +24.6%
2029 (forecast) $3.36 Bn +$237.0 Mn +34%
2030 (forecast) $3.61 Bn +$255.0 Mn +44.2%
2031 (forecast) $3.89 Bn +$274.4 Mn +55.2%
2032 (forecast) $4.18 Bn +$295.3 Mn +67%
2033 (forecast) $4.50 Bn +$317.7 Mn +79.7%
2034 (forecast) $4.84 Bn +$341.9 Mn +93.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $36.64 Bn
  2. North America $19.83 Bn
  3. US $14.53 Bn
  4. Europe $7.05 Bn
  5. APAC $6.98 Bn
  6. Canada $3.12 Bn
  7. China $2.87 Bn
  8. Japan (this report) $2.50 Bn
  9. Latin America $1.85 Bn
  10. Germany $1.49 Bn
  11. Middle East $1.42 Bn
  12. France $1.07 Bn
  13. UK $1.01 Bn
  14. Brazil $946.0 Mn
  15. Italy $875.8 Mn
  16. Ecuador $761.7 Mn
  17. Spain $723.5 Mn
  18. India $715.7 Mn
  19. Africa $648.4 Mn
  20. Saudi Arabia $632.0 Mn
  21. Mexico $592.4 Mn
  22. Australia $415.7 Mn
  23. Russia $383.0 Mn
  24. New Zealand $363.3 Mn
  25. South Africa $220.7 Mn
  26. UAE $206.2 Mn
  27. Egypt $92.1 Mn
  28. Philippines $89.0 Mn
  29. Malaysia $65.4 Mn
  30. Hong Kong $54.1 Mn
  31. Singapore $42.8 Mn
  32. Thailand $39.9 Mn
  33. Kenya $23.7 Mn

Report snapshot

Japan Plasma-Derived Therapies Market Analysis at a glance
Market size, 2025$2.50 Bn placeholder estimate
Forecast, 2034$4.84 Bn placeholder estimate
Growth (CAGR), 2025–20347.6% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsProduct, application and end user (see all)
Key playersCSL Behring, Takeda Pharmaceutical Company Ltd, Grifols, Octapharma, Kedrion Biopharma (see all)
Regulator in JapanPMDASource: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Japan Plasma-Derived Therapies Market Analysis Executive Summary

Plasma-derived therapies are medicines made from donated blood plasma, such as immunoglobulins, albumin and clotting factors.

Key segments of the plasma-Derived Therapies market include product (Immunoglobulins, Albumin and Coagulation Factors) and application (Immunology, Hematology and Critical Care).

Bar chart: Japan Plasma-Derived Therapies market size, 2024–2034, placeholder estimates. $2.33 Bn in 2024, $2.50 Bn in 2025 and $4.84 Bn in 2034, 7.6% CAGR.
Japan Plasma-Derived Therapies market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Japan Plasma-Derived Therapies Market Dynamics

Market Growth Drivers

More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the plasma-Derived Therapies market.

Opportunity

Ready-to-use formulations, biosimilars and supply security programmes give the plasma-Derived Therapies market room to grow.

Market Restraints

Drug shortages, price controls, generic competition and strict hospital budgets hold back the plasma-Derived Therapies market.

Competitive Landscape for Plasma-Derived Therapies Market in Japan

The plasma-Derived Therapies market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Plasma-Derived Therapies Market in Japan

Plasma-Derived Therapies in Japan: rules and payment

Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW).⁠[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).⁠[2]

[1] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[2] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for plasma-Derived Therapies. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Japan.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Plasma-Derived Therapies right now, from free public sources.

Latest research 1,017 papers since 2021 (worldwide)

  1. Cold atmospheric plasma in yeast biotechnology for strain improvement and bioprocess stimulation. World journal of microbiology & biotechnology, 2026
  2. Development of a novel manufacturing process for highly purified and stable immunoglobulin M with enhanced plasma utilization. Vox sanguinis, 2026
  3. Plasma-derived hyperhomocysteinemia, PGAM5, and oligomeric α-synuclein as a biomarker panel for idiopathic Parkinson's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026
  4. Comparative effects of mesenchymal stem cell- and platelet-rich plasma-derived extracellular vesicles on peripheral nerve regeneration following sciatic nerve crush injury. Journal of molecular histology, 2026
  5. Comment on: Protection of fundamental human rights by improving patient access to plasma-derived therapies and donor health protection. Vox sanguinis, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Plasma-Derived Therapies in context

Japan compared

  • Health spending per person: 3,638 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.65 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 5th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 30.0% of people (2025). World: 10.4% of people (2025). Highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 14 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 14 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 15 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Plasma-Derived Therapies market in Japan?
Placeholder estimate: about $2.50 Bn in 2025, rising to about $4.84 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Plasma-Derived Therapies market in Japan growing?
Placeholder estimate: about 7.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Plasma-Derived Therapies market report cover?
The report splits the market by product (Immunoglobulins, Albumin, Coagulation Factors, Alpha-1 Antitrypsin), application (Immunology, Hematology, Critical Care, Neurology) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Plasma-Derived Therapies market?
Key players include CSL Behring, Takeda Pharmaceutical Company Ltd, Grifols, Octapharma and Kedrion Biopharma.
What is driving the Plasma-Derived Therapies market?
More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the plasma-Derived Therapies market.
Who regulates Plasma-Derived Therapies in Japan?
Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW). Source: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
How is healthcare paid for in Japan?
Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices). Source: Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
How much research is published on Plasma-Derived Therapies?
PubMed lists 1,017 papers on Plasma-Derived Therapies added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Plasma-Derived Therapies in Japan? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Patient Support Programmes: Helping Patients Stay on TreatmentWHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient… Biologic Safety Testing: The Quiet Backbone of Drug MakingEvery vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches… Cell-Based Immunotherapy: Promise and PriceThe first CAR-T cell therapy was approved in the US in August 2017. These living drugs can work when other…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Japan

See all
Same topic, other categories

Related on biologics and biosimilars

See the topic